Skip to content
Skip to navigation menu

 

Dr Steve Hood and Dr Richard Kirsh

Starts: 14 May 2014

Wednesday 14th May 2014 

GSK, UK and USA

The Challenges of Transforming Oligonucleotides from Research Molecules into Reimbursable Medicines

Steve Hood PhD
Steve studied for his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral fellow in 1993 where he produced recombinant drug metabolising enzymes for the DMPK department.

Following the formation of GSK in 2001, Steve managed a team determining the Drug-Drug interaction liabilities of co-medicated drugs while developing ADME strategies for the emerging GSK antibody portfolio.

In 2010, Steve joined a cross divisional team charged with understanding and overcoming of the delivery issues inherent in GSK’s diverse oligonucleotide portfolio. Steve is currently the Director of the GSK Oligonucleotide Delivery (GOLD) team and Co-coordinator of the IMI COMPACT project, a European Consortium that includes researchers from the Cardiff School of Pharmacy and Pharmaceutical Sciences and the School of Biosciences Cardiff University .

Location

Paul Spencer Lecture Theatre, Redwood (2.60C)

Refreshments from 1:20pm

Host

Dr Chris Allender

Position:Senior Lecturer
Staff Photo
Telephone: +44 (0)29 208 75824Extension: 75824

 

Other information

Open To: Public
Staff and Students
Undergraduate Students